** Shares of drug developer Ensysce Biosciences ENSC.O rise 63.6% to 71 cents premarket

** Co says it has received a $14 mln multi-year grant from the National Institutes of Health and National Institute on Drug Abuse for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection

** Funding from this award will be available over a period of about three years, allowing for the completion of an early-stage trial on the drug

** With this funding, adding to the two prior grants of over $26 mln, Ensysce intends to quickly drive PF614-MPAR through clinical development, co says

** The drug is designed to provide optimal pain relief at prescribed doses, yet limit accidental or intentional overdose by 'shutting down' opioid release if too much active drug is consumed - ENSC

** Up to last close, stock down 58.7% YTD

(Reporting by Sneha S K)

(( Sneha.SK@thomsonreuters.com ;))

(c) Copyright Thomson Reuters 2024. Click For Restrictions - https://agency.reuters.com/en/copyright.html